7.55
-0.24 (-3.08%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Alumis Inc. | Mixed | - |
AIStockmoo Score
Analyst Consensus | 4.0 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 1.5 |
Technical Oscillators | -2.0 |
Average | 1.00 |
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
Sector | Healthcare |
Industry | Biotechnology |
% Held by Insiders | 1.21% |
% Held by Institutions | 74.78% |
Ownership
Name | Date | Shares Held |
---|---|---|
Ayurmaya Capital Management Company, Lp | 30 Sep 2024 | 10,645,965 |
Foresite Capital Management V, Llc | 30 Sep 2024 | 5,584,889 |
Yu Fan | 30 Sep 2024 | 789,618 |
52 Weeks Range | ||
Price Target Range | ||
High | 32.00 (Oppenheimer, 323.84%) | Buy |
Median | 25.50 (237.75%) | |
Low | 19.00 (HC Wainwright & Co., 151.66%) | Buy |
Average | 25.50 (237.75%) | |
Total | 2 Buy | |
Avg. Price @ Call | 6.93 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 07 Feb 2025 | 19.00 (151.66%) | Buy | 7.13 |
06 Jan 2025 | 26.00 (244.37%) | Buy | 8.79 | |
Oppenheimer | 30 Jan 2025 | 32.00 (323.84%) | Buy | 6.72 |
No data within this time range.
Date | Type | Details |
---|---|---|
10 Feb 2025 | Announcement | Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference |
06 Feb 2025 | Announcement | Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases |
28 Jan 2025 | Announcement | Alumis Strengthens Leadership Team with Key Appointments |
19 Dec 2024 | Announcement | Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 |
14 Nov 2024 | Announcement | Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |